Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions

Journal of Cardiothoracic Surgery

Volumn 7, Issue 1, 2012, Pages

  Klimatsidas, Michail ^a   Anastasiadis, Kyriakos ^c   Foroulis, Christophoros ^c   Tossios, Paschalis ^c   Bisiklis, Alexandros ^b   Papakonstantinou, Christos ^c   Rammos, Kyriakos ^c  

^a 424 General Army Hospital   (Greece)

^b 212 Military Hospital of Greece   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17;

ADULT; AGE; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PLEURA EFFUSION;

ADULT; AGE FACTORS; AGED; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-17; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; STATISTICS, NONPARAMETRIC;

MLCS; MLOWN;

EID: 84866927118     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-7-104     Document Type: Article

References (24)

1. Sai Y, Chukwumere N, Demmy TL. Malignant Pleural and Pericardial Effusions. Sabiston & Spencer Surgery of the Chest. Volume 1. 8th edn 2010, Saunders Elsevier, Selke.
2. Light RW. Pleural diseases. Dis Mon 1992, 38:261-331.
3. McGrath EE, Warriner D, Anderson PB. The use of non-routine pleural fluid analysis in the diagnosis of pleural effusion. Respir Med 2010, 104:1092-1100. 10.1016/j.rmed.2010.03.008, 20392619.
4. Atwell DM, Grichnik KP, Newman MF, Reves JG, McBride WT. Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. Ann Thorac Surg 1998, 66:1145-1150. 10.1016/S0003-4975(98)00592-X, 9800796.
5. Marincola FM. Interleukin-10 2006, Landes Bioscience, Georgetown, Eurekah.com.
6. Oppenheim JJ, Feldmann M, Durum SK. Cytokine reference: a compendium of cytokines and other mediators of host defense 2001, Academic, San Diego.
7. Durum SK. Cytokines and the Immune System. Cytokine Reference: a compendium of cytokines and other mediators of host defense. Volume 1. First edn 2001, Academic Press, London, UK, Oppenheim JJ, Feldmann M.
8. Li Y, Anderson GM, Mark D, Marian TN. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. European journal of cancer (Oxford, England: 1990) 2006, 42:793-802.
9. Szlosarek P, Balkwill F. The inflammatory cytokine network of epithelial cancer: therapeutic implications. Novartis Found Symp 2004, 256:227-237. discussion 237-240, 259-269.
10. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994, 145:18-25. 1887307, 8030748.
11. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000, 117:365-373. 10.1378/chest.117.2.365, 10669676.
12. Chen YM, Yang WK, Whang-Peng J, Kuo BI, Perng RP. Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996, 110:433-436. 10.1378/chest.110.2.433, 8697847.
13. Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2003, 9:1785-1791.
14. Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 2000, 11:815-819. 10.1023/A:1008375208574, 10997808.
15. Zeng L, O'Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 2010, 49:294-302. 10.1016/j.cyto.2009.11.015, 20034810.
16. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol 2003, 57:173-178. 10.1046/j.1365-3083.2003.01205.x, 12588664.
17. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
18. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006, 42:760-767. 10.1016/j.ejca.2006.01.002, 16510278.
19. Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr Opin Pharmacol 2009, 9:351-369. 10.1016/j.coph.2009.06.020, 2730981, 19665429.
20. Rous P, Kidd JG. Conditional neoplasms and subthreshold neoplastic states: a study of the tar tumors of rabbits. J Exp Med 1941, 73:365-390. 10.1084/jem.73.3.365, 2135131, 19871084.
21. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
22. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603. 10.1084/jem.183.6.2593, 2192621, 8676080.
23. Serge L, Francois F, Bates E. IL-17. Cytokine Reference: a compendium of cytokines and other mediators of host defense. Volume 1 2001, Academic Press, London, UK, Oppenheim JJ, Feldmann M.
24. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002, 71:1-8.